Asaf Danziger

Asaf Danziger

DirectoratNovoCure· In proxies 2021–2025

Pay in FY2022+96% from the year before · NovoCure stock -2.3% the same year

Asaf Danziger was paid $2.3M in FY2022 (Dec), up 96%. NovoCure stock fell 2.3% that year.

Pay$100 in the stock at the end of FY20 → $42
Pay is from the Summary Compensation Table of each NovoCure proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NovoCurePublic company · 5 yr
    • Director2021 – Present · 5 yrStock in role -92%

Roles come from the proxy statements of each company.

Boards1

  • NovoCureDirector · 13 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?